Bayesian Capital Management, LP - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 357 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.

Quarter-by-quarter ownership
Bayesian Capital Management, LP ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$1,662,827
+16.1%
46,100
+22.9%
0.18%
+1.1%
Q1 2023$1,432,125
+231.2%
37,500
+393.4%
0.18%
+181.0%
Q4 2022$432,440
-32.1%
7,600
-52.8%
0.06%
-51.2%
Q3 2022$637,000
-27.3%
16,100
-19.1%
0.13%
-20.9%
Q2 2022$876,000
+147.5%
19,900
+155.1%
0.16%
+77.2%
Q2 2021$354,000
+0.3%
7,800
-7.9%
0.09%
+13.6%
Q1 2021$353,000
-23.6%
8,465
-62.9%
0.08%
-13.8%
Q4 2017$462,000
+376.3%
22,800
+103.6%
0.09%
+62.1%
Q2 2016$97,00011,2000.06%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q3 2022
NameSharesValueWeighting ↓
Third Security, LLC 1,129,551$47,091,0006.38%
First Light Asset Management, LLC 2,011,350$83,853,0005.56%
TRAN CAPITAL MANAGEMENT, L.P. 1,353,208$56,415,0005.03%
SNYDER CAPITAL MANAGEMENT L P 2,920,860$121,771,0003.50%
DOHENY ASSET MANAGEMENT /CA 120,028$5,004,0003.39%
SILVERARC CAPITAL MANAGEMENT, LLC 104,945$4,375,0002.39%
Redwood Investments, LLC 542,764$22,628,0001.99%
Kent Lake Capital LLC 85,000$3,544,0001.44%
Lisanti Capital Growth, LLC 263,460$10,984,0001.41%
Bellevue Group AG 3,011,966$125,569,0001.33%
View complete list of HALOZYME THERAPEUTICS INC shareholders